Q3 2022 13F Holders as of 30 Sep 2022
-
Type / Class
-
Equity / Common shares, Euro 0.12 nominal value per share
-
Shares outstanding
-
26,019,256
-
Total 13F shares
-
7,452,823
-
Share change
-
-386,481
-
Total reported value
-
$34,059,026
-
Price per share
-
$4.57
-
Number of holders
-
12
-
Value change
-
-$58,919
-
Number of buys
-
4
-
Number of sells
-
8
Institutional Holders of LAVA Therapeutics NV - Common shares, Euro 0.12 nominal value per share (LVTX) as of Q3 2022
As of 30 Sep 2022,
LAVA Therapeutics NV - Common shares, Euro 0.12 nominal value per share (LVTX) was held by
12 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
7,452,823 shares.
The largest 10 holders included
Novo Holdings A/S, Redmile Group, LLC, SILVERARC CAPITAL MANAGEMENT, LLC, AXA S.A., Artal Group S.A., Alpha Wave Global, LP, UBS OCONNOR LLC, MILLENNIUM MANAGEMENT LLC, CANNELL CAPITAL LLC, and GEODE CAPITAL MANAGEMENT, LLC.
This page lists
12
institutional shareholders reporting positions in this security
for the Q3 2022 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.